Researcher/sponsor bias and fraud

The commercial, academic or other vested interests of researchers and organizations tend to be reflected in reports of treatment research in which they are involved.


JLL Essay
2.9 Recognizing researcher/sponsor biases and fraud

Publish all the results and make them accessible, Produce unbiased and useful research reports

 

FILTER CLEAR FILTERS

SORT date author


FILTER RECORDS BY


Sollmann T (1917)
The crucial test of therapeutic evidence. JAMA 69:198-199.

View

Hemminki E (1980)
Study of information submitted by drug companies to licensing authorities. BMJ 280:833-6.

View

Davidson RA (1986)
Source of funding and outcome of clinical trials. Journal of General Internal Medicine 1:156-158.

View

Gøtzsche PC (1987)
Reference bias in reports of drug trials. BMJ 295:654-656.

View

Gøtzsche PC (1989)
Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Control Clinical Trials 10:31-56.

View

Blumenthal D, Gluck M, Louis KS, Stoto MA, Wise D. (1996)
Academic-industry relationships in the life sciences - an industry survey. New England Journal of Medicine 334:368-73.

View

Djulbegovic B, Lacevic M, Cantor A, Fields KK, Bennett CL, Adams JR, Kuderer NM, Lyman GH (2000)
The uncertainty principle and industry-sponsored research. Lancet 356:635-638.

View

Lexchin J, Bero LA, Djulbegovic B, Clark O (2003)
Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 326:1167-70.

View

Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B (2003)
Evidence b(i)ased medicine - selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ 326:1171-3.

View

Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E (2004)
Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet; 363:1341-1345.

View

Yank V, Rennie D, Bero LA (2007)
Financial ties and concordance between results: retrospective cohort study. BMJ 335:1202-5. doi:10.1136/bmj.39376.447211.

View

Djulbegovic B, Kumar A, Soares HP, Hozo I, Bepler G, Clarke M, Bennett CL (2008)
Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the national cancer institute-sponsored cooperative oncology groups, 1955 to 2006. Archives of Internal Medicine. 168:632-42.

View

Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R (2008)
Selective publication of antidepressant trials and its influence on apparent efficacy. New England Journal of Medicine 358:252-60.

View

Rising K, Bacchetti P, Bero L (2008)
Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation. PLoS Med 5(11): e217. doi:10.1371/journal.pmed.0050217

View

Psaty BM, Kronmal RA (2008)
Reporting mortality findings in trials of Rofecoxib for Alzheimer disease or cognitive impairment. JAMA 299:1813-1817.

View

De Barra M, Erikson K, Strimling P (2014)
How feedback biases give ineffective medical treatments a good reputation. Journal of Medical Internet Research Res 16:e193. doi:10.2196/jmir.3214

View

Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, Spencer EA, Onakpoya I, Mahtani KR, Nunan D, Howick J, Heneghan CJ (2014)
Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database of Systematic Reviews 2014, Issue 4. Art. No.: CD008965. DOI:10.1002/14651858.CD008965.pub4.

View

Misemer BS, Platts-Mills TF, Jones CW (2016)
Citation bias favoring positive clinical trials of thrombolytics for acute ischemic stroke: a cross-sectional analysis. Trials 17:473.

View

Bradley SH, DeVito NJ, Lloyd KE, Richards GC, Rombey T, Wayant C, Gill PJ (2020)
Reducing bias and improving transparency in medical research: a critical overview of the problems, progress and suggested next steps. Journal of the Royal Society of Medicine 113:433-443.

View

Show


Altman DG† (2017).
Donald Mainland: anatomist, educator, thinker, medical statistician, trialist, rheumatologist. JLL Bulletin: Commentaries on the history of treatment evaluation.

View

Jefferson T (2019).
Sponsorship bias in clinical trials – growing menace or dawning realisation? JLL Bulletin: Commentaries on the history of treatment evaluation.

View

Gøtzsche PC (2021).
Citation bias: questionable research practice or scientific misconduct? JLL Bulletin: Commentaries on the history of treatment evaluation.

View